RP1 + Nivolumab in Patients with Advanced Anti–PD-1–Failed Acral Melanoma at ESMO 2025

Replimune Group Inc. published this content on October 18, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 18, 2025 at 07:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]